Hibernaid is a privately held company developing unique drugs and devices for important acute medical indications in high-risk critical care patient populations, as well as unique treatments targeting underserved chronic indications. The Company's lead development compound is HBN-1, a unique IV combination drug that pharmaceutically induces clinically-relevant regulated hypothermia (deliberate reduction of core body temperature) to prevent neurological, functional and organ damage and significantly increase the probability of survival in a broad range of acute care medical conditions. HBN-1 is initially being developed for use in resuscitated post-cardiac arrest patients but the technology will also be developed for the treatment of stroke, traumatic brain injury, spinal cord injury and other acute critical care indications. The Company is also developing important new drugs and devices to treat a variety of medical indications, most notably severe sepsis and septic shock (critical care), as well as mild concussion (including sports related injuries), Progeria, an orphan indication that causes premature aging and early death in children and menopausal-related 'hot flashes'.
View Top Employees from HIBERNAID INC. NAIDWebsite | http://hibernaid.com |
Revenue | $1 million |
Employees | View employees |
Address | 70 COONS RD, Troy, New York 12180, US |
Phone | (518) 279-9297 |
Fax | (518) 279-9047 |
Technologies | |
Industry | Drug Manufacturing & Research, Pharmaceuticals, Healthcare |
SIC | SIC Code 384 Companies, SIC Code 38 Companies |
NAICS | NAICS Code 339 Companies, NAICS Code 33 Companies |
Looking for a particular HIBERNAID INC. NAID employee's phone or email?
The HIBERNAID INC. NAID annual revenue was $1 million in 2023.
HIBERNAID INC. NAID is based in Troy, New York.
The NAICS codes for HIBERNAID INC. NAID are [339, 33].
The SIC codes for HIBERNAID INC. NAID are [384, 38].